Patients with HER2 gene amplification, normal left ventricular ejection fraction (LVEF), and resistant relapse after first- or second-line paclitaxel/carboplatin chemotherapy received paclitaxel ...

D uring a shortage of the generic platinum chemotherapy drugs cisplatin and carboplatin that began in early 2023, there was no difference in mortality rates among patients with advanced cancer ...

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation ...

IMUNON (IMNN) announced that the U.S. Food and Drug Administration is aligned with the protocol for the Phase 3 pivotal trial, called OVATION ...

BRCA1/2 mutation carriers exhibited a more pronounced pathologic complete response rate, especially with carboplatin. The study predates the immunotherapy era, necessitating contextual interpretation ...

Positive opinion for first-line treatment of extensive-stage small cell lung cancer based on results of RATIONALE-312 study demonstrating statistically significant overall survival benefit for TEVIMBR ...

In this study, 32 patients (aged 8 months to 20 years) who were receiving cisplatin and/or carboplatin chemotherapy underwent baseline and serial CF audiometry and measurement of DPOAEs.

Thymic carcinoma, a rare cancer, is often associated with poor prognosis in advanced or recurrent stages. However, its rarity has delayed the development of novel pharmacotherapy. Now, researchers ...